Subject of the day
MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
FY 2015–2025 · 11 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $32.36B | +6.9% | |
| Gross profit | $5.66B | +12.3% | |
| Operating income | $5.14B | +3.0% | |
| Net income | $3.76B | +0.9% | |
| Cash from ops | $6.79B | +3.0% |
$90.58
▼ -0.18 (-0.2%)
| 52w hi | $102.81 |
|---|---|
| 52w lo | $73.09 |
| Vol | 4.97M |
| As of | Aug 13 |
Our score +0.11
| Short | -0.16 |
|---|---|
| Medium | +0.22 |
| Long | +0.42 |
computed 2026-08-13
Medtronic plc
Healthcare · Medical Devices
| Market cap | $115.95B |
|---|---|
| Enterprise value | $136.71B |
| Trailing P/E | 24.28x |
| Forward P/E | 14.13x |
| EV / EBITDA | 13.53x |
| P / S (ttm) | — |
| Profit margin | 13.2% |
| Return on equity | 9.8% |
| Revenue growth | +9.9% |
| Earnings growth | +18.3% |
| Debt / equity | 58.21 |
| Beta vs SPX | 0.38 |
|---|---|
| Corr SPX | 0.28 |
| Annual vol | 22.3% |
| Annual ret | +7.3% |
| Sharpe | 0.33 |
| Max DD | -30.0% |
Window: 504 trading days (504 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.30 | |
| Sector | +0.12 | |
| Technical | -0.03 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $91.44 | $91.61 | $90.41 | $90.58 | 4.97M |
| Aug 12 | $88.96 | $91.03 | $88.50 | $90.76 | 6.23M |
| Aug 11 | $89.26 | $90.73 | $88.70 | $90.68 | 8.39M |
| Aug 10 | $87.16 | $89.45 | $86.72 | $89.41 | 6.57M |
| Aug 7 | $85.46 | $87.19 | $84.96 | $87.16 | 5.06M |